Q-omics provides the consensus-scored CFL1P3 profile across patient tissues and cancer cell-line models. CFL1P3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CFL1P3 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, CFL1P3 RNA expression shows 14,967 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, BRCA, and LSCC as cancer lineages where CFL1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFL1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFL1P3 survival associations across molecular data types. CFL1P3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFL1P3 RNA expression–survival associations across cancer types. High CFL1P3 expression shows unfavorable associations in KICH, ACC, LAML and THYM, but favorable associations in LUSC and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CFL1P3 RNA expression.
This table summarizes CFL1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CFL1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFL1P3 shows lower tumor expression in LUSC and higher tumor expression in BRCA, KIRC, HNSC, KICH and LIHC. The BRCA box plot shows higher CFL1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.119, t-test p < 0.001).
This table shows molecular features associated with CFL1P3 in patient tissues and cancer cell lines. In patient samples, CFL1P3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
